DD203154A5 - Raegens zur praezipitation apo-b-haltiger lipoproteine, verfahren zu dessen herstellung und dessen verwendung bei der bestimmung von hdl-cholesterin - Google Patents

Raegens zur praezipitation apo-b-haltiger lipoproteine, verfahren zu dessen herstellung und dessen verwendung bei der bestimmung von hdl-cholesterin Download PDF

Info

Publication number: DD203154A5
Authority: DD; German Democratic Republic
Prior art keywords: reagent; sample; precipitation; apo; item
Prior art date: 1981-05-02

Application number

DD82239482A

Other languages

German (de)

English (en)

Inventor

Brigitte Draeger

Joachim Ziegenhorn

Original Assignee

Boehringer Mannheim Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-05-02

Filing date

1982-04-30

Publication date

1983-10-12

1982-04-30 Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh

1983-10-12 Publication of DD203154A5 publication Critical patent/DD203154A5/de

Links

102000004895 Lipoproteins Human genes 0.000 title claims abstract description 36
108090001030 Lipoproteins Proteins 0.000 title claims abstract description 36
238000000034 method Methods 0.000 title claims abstract description 34
239000003153 chemical reaction reagent Substances 0.000 claims abstract description 93
238000001556 precipitation Methods 0.000 claims abstract description 64
102000018616 Apolipoproteins B Human genes 0.000 claims abstract description 30
108010027006 Apolipoproteins B Proteins 0.000 claims abstract description 30
IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 claims abstract description 24
229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 17
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 16
238000002360 preparation method Methods 0.000 claims abstract description 5
239000007864 aqueous solution Substances 0.000 claims abstract description 3
239000003599 detergent Substances 0.000 claims description 43
230000001376 precipitating effect Effects 0.000 claims description 43
239000000243 solution Substances 0.000 claims description 24
239000002244 precipitate Substances 0.000 claims description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
239000006228 supernatant Substances 0.000 claims description 12
159000000003 magnesium salts Chemical class 0.000 claims description 8
-1 Polyoxyethylene Polymers 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 6
150000001346 alkyl aryl ethers Chemical class 0.000 claims description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
229920000259 polyoxyethylene lauryl ether Polymers 0.000 claims description 3
FFQUUCADLBSLBR-UHFFFAOYSA-L disodium;2-dodecyl-2-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCCCCCC(S(O)(=O)=O)(C([O-])=O)CC([O-])=O FFQUUCADLBSLBR-UHFFFAOYSA-L 0.000 claims description 2
229960000878 docusate sodium Drugs 0.000 claims 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
125000000129 anionic group Chemical group 0.000 claims 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 72
239000000523 sample Substances 0.000 description 45
108010010234 HDL Lipoproteins Proteins 0.000 description 37
102000015779 HDL Lipoproteins Human genes 0.000 description 37
235000012000 cholesterol Nutrition 0.000 description 35
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 26
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
210000002966 serum Anatomy 0.000 description 15
238000005119 centrifugation Methods 0.000 description 14
229910001629 magnesium chloride Inorganic materials 0.000 description 13
239000011777 magnesium Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 8
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
235000011121 sodium hydroxide Nutrition 0.000 description 5
239000002904 solvent Substances 0.000 description 5
RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 4
238000012360 testing method Methods 0.000 description 4
GHTMQNZCRVHCQP-UHFFFAOYSA-J tetrasodium;4-[1,2-dicarboxyethyl(octadecyl)amino]-4-oxo-2-sulfobutanoate Chemical compound [Na+].[Na+].[Na+].[Na+].CCCCCCCCCCCCCCCCCCN(C(CC(O)=O)C(O)=O)C(=O)CC(C([O-])=O)S(O)(=O)=O.CCCCCCCCCCCCCCCCCCN(C(CC(O)=O)C(O)=O)C(=O)CC(C([O-])=O)S(O)(=O)=O.CCCCCCCCCCCCCCCCCCN(C(CC(O)=O)C(O)=O)C(=O)CC(C([O-])=O)S(O)(=O)=O.CCCCCCCCCCCCCCCCCCN(C(CC(O)=O)C(O)=O)C(=O)CC(C([O-])=O)S(O)(=O)=O GHTMQNZCRVHCQP-UHFFFAOYSA-J 0.000 description 4
108010023302 HDL Cholesterol Proteins 0.000 description 3
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000001000 lipidemic effect Effects 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
108010089254 Cholesterol oxidase Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
108010055297 Sterol Esterase Proteins 0.000 description 2
102000000019 Sterol Esterase Human genes 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000005259 measurement Methods 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000010998 test method Methods 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
PBYZMCDFOULPGH-UHFFFAOYSA-N tungstate Chemical compound [O-][W]([O-])(=O)=O PBYZMCDFOULPGH-UHFFFAOYSA-N 0.000 description 2
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
WDNBURPWRNALGP-UHFFFAOYSA-N 3,4-Dichlorophenol Chemical compound OC1=CC=C(Cl)C(Cl)=C1 WDNBURPWRNALGP-UHFFFAOYSA-N 0.000 description 1
FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
108010004103 Chylomicrons Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
101710109723 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Proteins 0.000 description 1
102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000000923 atherogenic effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
239000012470 diluted sample Substances 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
GYQQNCSTNDNVMM-UHFFFAOYSA-L disodium 4-(octadecylamino)-4-oxo-2-sulfobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCCCCCCCNC(=O)CC(C([O-])=O)S(O)(=O)=O.CCCCCCCCCCCCCCCCCCNC(=O)CC(C([O-])=O)S(O)(=O)=O GYQQNCSTNDNVMM-UHFFFAOYSA-L 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
239000011654 magnesium acetate Substances 0.000 description 1
235000011285 magnesium acetate Nutrition 0.000 description 1
229940069446 magnesium acetate Drugs 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
229910001437 manganese ion Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000001139 pH measurement Methods 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
CMPGARWFYBADJI-UHFFFAOYSA-L tungstic acid Chemical compound O[W](O)(=O)=O CMPGARWFYBADJI-UHFFFAOYSA-L 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Hematology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

DD82239482A 1981-05-02 1982-04-30 Raegens zur praezipitation apo-b-haltiger lipoproteine, verfahren zu dessen herstellung und dessen verwendung bei der bestimmung von hdl-cholesterin DD203154A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19813117455 DE3117455A1 (de)	1981-05-02	1981-05-02	Reagens zur praezipitation apo-b-haltiger lipoproteine, verfahren zu dessen herstellung und dessen verwendung bei der bestimmung von hdl-cholesterin

Publications (1)

Publication Number	Publication Date
DD203154A5 true DD203154A5 (de)	1983-10-12

Family

ID=6131335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD82239482A DD203154A5 (de)	1981-05-02	1982-04-30	Raegens zur praezipitation apo-b-haltiger lipoproteine, verfahren zu dessen herstellung und dessen verwendung bei der bestimmung von hdl-cholesterin

Country Status (7)

Country	Link
US (1)	US4521519A (fr)
EP (1)	EP0064665B1 (fr)
JP (1)	JPS57186171A (fr)
AT (1)	ATE12699T1 (fr)
CA (1)	CA1192822A (fr)
DD (1)	DD203154A5 (fr)
DE (2)	DE3117455A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0180720B1 (fr) *	1981-09-10	1990-06-13	B. Braun-SSC AG	Dispositif pour la précipitation sélective extracorporelle des lipoprotéines à basse densité dans du sérum et du plasma sanguin
DE3215310A1 (de) *	1982-04-23	1983-10-27	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren zur bestimmung der low density lipoproteine (ldl) und reagenz zu seiner durchfuehrung
US5149501A (en) *	1990-01-29	1992-09-22	Cirrus Diagnostics, Inc.	Multichambered container and instrument for performing diagnostic tests
US5168067A (en) *	1990-05-25	1992-12-01	Miller Michael A	Method and kit for screening for apolipoprotein b or calculated ldl cholesterol
US5460974A (en) *	1992-10-13	1995-10-24	Miles Inc.	Method of assaying whole blood for HDL cholesterol
JPH0648044U (ja) *	1992-11-26	1994-06-28	三菱樹脂株式会社	メモリカード読み書き装置
JP2600065B2 (ja) *	1994-03-08	1997-04-16	協和メデックス株式会社	高密度リポ蛋白中のコレステロールの定量法
US5770451A (en) *	1995-03-30	1998-06-23	Streck Laboratories, Inc.	Liquid lipoprotein control
US5614414A (en) *	1995-03-30	1997-03-25	Streck Laboratories, Inc.	Liquid lipoprotein control
CN100577812C (zh) *	2002-10-16	2010-01-06	协和梅迪克斯株式会社	高密度脂蛋白中的胆固醇的测定方法以及试剂
WO2004053500A1 (fr) *	2002-12-06	2004-06-24	Denka Seiken Co., Ltd.	Procede permettant de quantifier une lipoproteine de petite taille et de basse densite
US7521248B2 (en) *	2007-04-20	2009-04-21	Atherotech, Inc.	Apo B measurement system and method
EP2065708B1 (fr)	2007-11-28	2014-01-01	FUJIFILM Corporation	Procédé de mesure de cholestérol de lipoprotéine à forte densité
JP5313537B2 (ja)	2008-04-10	2013-10-09	富士フイルム株式会社	高密度リポ蛋白コレステロール測定用乾式分析素子
US20120107850A1 (en) *	2009-07-15	2012-05-03	Panasonic Corporation	Analysis reagent and analysis device having the analysis reagent carried therein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT320865B (de) *	1973-02-12	1975-03-10	Immuno Ag	Verfahren zum Bestimmen von normalen und pathologischen Plasma-Lipoproteinen in menschlichen Körperflüssigkeiten und Apparat zur Durchführung des Verfahrens
US4226713A (en) *	1978-04-24	1980-10-07	Goldberg Jack M	Diagnostic agents
US4215993A (en) *	1978-12-04	1980-08-05	Data Medical Associates, Inc.	Precipitating reagent and method for isolation and determination of high density lipoproteins in human serum
US4210557A (en) *	1978-12-15	1980-07-01	Beckman Instruments, Inc.	Non-high density lipoprotein precipitant
DE2944138A1 (de) *	1979-11-02	1981-06-11	Technicon Gmbh, 6368 Bad Vilbel	Verfahren und vorrichtung zur durchfuehrung von analysen in automatischen analysensystemen unter abtrennung von niederschlaegen

1981
- 1981-05-02 DE DE19813117455 patent/DE3117455A1/de not_active Withdrawn
1982
- 1982-04-19 US US06/369,382 patent/US4521519A/en not_active Expired - Lifetime
- 1982-04-27 AT AT82103570T patent/ATE12699T1/de not_active IP Right Cessation
- 1982-04-27 EP EP82103570A patent/EP0064665B1/fr not_active Expired
- 1982-04-27 DE DE8282103570T patent/DE3262945D1/de not_active Expired
- 1982-04-29 CA CA000401988A patent/CA1192822A/fr not_active Expired
- 1982-04-30 DD DD82239482A patent/DD203154A5/de not_active IP Right Cessation
- 1982-05-04 JP JP57073506A patent/JPS57186171A/ja active Granted

Also Published As

Publication number	Publication date
JPH0139553B2 (fr)	1989-08-22
EP0064665B1 (fr)	1985-04-10
DE3117455A1 (de)	1982-11-25
CA1192822A (fr)	1985-09-03
US4521519A (en)	1985-06-04
ATE12699T1 (de)	1985-04-15
EP0064665A1 (fr)	1982-11-17
DE3262945D1 (en)	1985-05-15
JPS57186171A (en)	1982-11-16

Legal Events

Date	Code	Title	Description
1996-04-25	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD203154A5 (de)	1983-10-12	Raegens zur praezipitation apo-b-haltiger lipoproteine, verfahren zu dessen herstellung und dessen verwendung bei der bestimmung von hdl-cholesterin
EP0184765B1 (fr)	1991-05-02	Sérum de contrôle ou standard pour le diagnostic lipidique
EP0012184B1 (fr)	1981-12-30	Solution hémolytique, utilisation d'une telle solution pour la détermination du glucose dans le sang, et procédé hémolytique
DE2333883C3 (de)	1983-05-11	Verfahren zur Herstellung von hochgereinigtem Humanalbumin
DE3338836A1 (de)	1985-05-09	Verfahren zur bestimmung der low density lipoproteine (ldl) und reagenz zu seiner durchfuehrung
EP0083773B1 (fr)	1985-05-22	Procédé pour la préparation d'une thromboplastine tissulaire composition
EP0088420A2 (fr)	1983-09-14	Procédé de dosage spécifique de cholestérol en fraction LDL dans le sérum
DE2943423C2 (fr)	1987-12-10
DE69716064T2 (de)	2004-01-08	Flüssigkeit zum sammeln von proben
EP0035211B1 (fr)	1983-12-28	Procédé et réactif pour la détermination de bêta-lipoprotéines (L.D.L.)
DE3851923T2 (de)	1995-04-27	Reagenz zur Retikulozytenzählung mittels Durchflusszytometrie.
EP0120220B1 (fr)	1988-03-23	Méthode et réactif pour la détermination du glucose dans le sang hémolisé
DE2361169C3 (de)	1978-09-14	Verfahren zur Aktivierung von von Detengensspuren befreiter Cholesterinoxydase
DE2534249A1 (de)	1976-02-12	Waessrige flotationsloesung
CH632092A5 (de)	1982-09-15	Verfahren und mittel zur bestimmung von hydroperoxiden.
DE3007579C2 (de)	1982-04-01	Selektives Medium zur Isolierung von Choleravibrionen
DE69600512T2 (de)	1999-04-15	Stabilisierte Troponin-Zubereitung für Immunoassays und Verfahren zur deren Herstellung
EP0067394B1 (fr)	1985-03-20	Solution étalon aqueuse de cholestérol et son procédé de préparation
DE3138602C2 (fr)	1993-02-11
DE2032270A1 (de)	1970-12-23	Diagnostische Reagenzien für die Bestimmung von gamma-Glutamyltranspeptidase im menschlichen Serum
DE2517545A1 (de)	1975-11-13	Verfahren zur spektrometrischen bestimmung von anorganischem phosphat und waessrige loesung zur durchfuehrung desselben
DE69030135T2 (de)	1997-06-19	Ein Reagenssystem zur Bestimmung von Lipase
DE3234761C2 (fr)	1991-07-25
EP0041704B1 (fr)	1985-01-09	Procédé et agent pour la dissolution des chilomicrones dans un milieu aqueux
DE2857710A1 (de)	1981-04-16	Bestimmung von ldl-cholesterin in koerperfluiden